Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biogen Idec (NQ: BIIB ) 205.00 +1.68 (+0.83%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Biogen Idec < Previous 1 2 3 4 5 6 7 8 9 ... 46 47 Next > Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday February 14, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Biogen (BIIB) Q4 2023 Earnings Call Transcript February 13, 2024 BIIB earnings call for the period ending December 31, 2023. Via The Motley Fool Topics Earnings Exposures Financial Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday? February 13, 2024 Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report. Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities Breaking Down Biogen: 8 Analysts Share Their Views February 13, 2024 Via Benzinga Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit February 13, 2024 The company missed both sales and earnings expectations for the fourth quarter. Via Investor's Business Daily Looking At Biogen's Recent Unusual Options Activity February 12, 2024 Via Benzinga Why Is Biogen Stock Trading Lower On Tuesday? February 13, 2024 Biogen's Q4 2023 performance, with $2.39 billion in sales, adjusted EPS of $2.95, and updates on key drugs. Via Benzinga Nasdaq, S&P 500 Set For Weaker Open As Traders Keep Eyes Peeled On Inflation Data: Analyst Flags Key CPI Report Item To Watch February 13, 2024 Despite the Fed rhetoric about the inflation fight being still on, the central bank will likely cut rates this year, an analyst said. Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia February 12, 2024 From Biogen Inc. Via GlobeNewswire Here's How Much You Would Have Made Owning Biogen Stock In The Last 20 Years February 09, 2024 Via Benzinga Critical Insights From Biogen Analyst Ratings: What You Need To Know January 24, 2024 Via Benzinga $1000 Invested In This Stock 20 Years Ago Would Be Worth $6,100 Today January 11, 2024 Via Benzinga Earnings Scheduled For February 13, 2024 February 13, 2024 Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. Via Benzinga Comparing Biogen With Industry Competitors In Biotechnology Industry January 10, 2024 Via Benzinga 3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good February 12, 2024 For patient, long-term investors, these three underestimated names can easily become millionaire-maker stocks. Via InvestorPlace 7 Biotech Stocks Fighting America’s Deadliest Diseases February 08, 2024 Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. Via InvestorPlace Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines January 31, 2024 Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval. Via Benzinga Exposures Product Safety Biogen to Realign Resources for Alzheimer's Disease Franchise January 31, 2024 From Biogen Inc. Via GlobeNewswire NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 January 29, 2024 Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and... Via Benzinga AT&T To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday January 25, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts January 24, 2024 UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy. Via Benzinga Highlights From the 2024 JPMorgan Health Care Conference January 22, 2024 Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Via The Motley Fool These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street January 18, 2024 Nice gains could be on the way for three stocks if analysts are right. Via The Motley Fool Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns January 12, 2024 A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer's detection. Via Benzinga Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments January 10, 2024 Wednesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million. Via Benzinga 2 low-priced gene therapy stocks to speculate on January 08, 2024 Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe Via MarketBeat Exposures Product Safety Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 January 05, 2024 Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. Via Investor's Business Daily Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024 January 03, 2024 These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky. Via The Motley Fool 3 Biotech Stocks at the Forefront of the Quest for Eternal Youth January 02, 2024 Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today. Via InvestorPlace Government-granted Patent Monopolies Are Not The Free Market December 29, 2023 Our system for developing new drugs is a disaster. While we can point to great successes, they come at enormous cost. We will spend over $600B this year on prescription and non-prescription drugs -... Via Talk Markets Topics Intellectual Property Exposures Intellectual Property < Previous 1 2 3 4 5 6 7 8 9 ... 46 47 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.